Tardive dyskinesia - Revision history

ClaireLewis at 16:36, 3 October 2019

2019-10-03T16:36:15Z

← Revisión anterior		Revisión del 16:36 3 oct 2019
Línea 1:		Línea 1:
	==Background==		==Background==

			==Clinical Features==
	*Orofacial involuntary movements		*Orofacial involuntary movements
	**Described as grimacing, writhing and choreathetoid		**Described as grimacing, writhing and choreathetoid
	**Grimacing, ~~Tongue~~ movements, ~~Lip~~ smacking, ~~Excessive~~ eye blinking		**Grimacing, tongue movements, lip smacking, excessive eye blinking
	*Often occurs after years of treatment with neuroleptic agents		*Often occurs after years of treatment with [[antipsychotics\|neuroleptic agents]]
	*Risk factors:		*Risk factors:
	**Longer duration of neuroleptic treatment		**Longer duration of neuroleptic treatment
Línea 16:		Línea 18:

	==Management==		==Management==
	*Mild ~~Symptoms~~: ~~Cessation~~ of the neuroleptic drug or decreasing the dose, which rarely reverses symptoms		*Mild symptoms: cessation of the neuroleptic drug or decreasing the dose, which rarely reverses symptoms
	*Moderate to ~~Severe Symptoms~~: ~~Reserpine~~ and tetrabenazine		*Moderate to severe symptoms: reserpine and tetrabenazine
	*New drug approved 2017		*New drug approved 2017
	**Austedo ([[deutetrabenazine]]), previously approved for chorea due to Huntington's disease		**Austedo ([[deutetrabenazine]]), previously approved for chorea due to Huntington's disease

2018-10-10T22:35:25Z

Management

← Revisión anterior		Revisión del 22:35 10 oct 2018
Línea 19:		Línea 19:
	*Moderate to Severe Symptoms: Reserpine and tetrabenazine		*Moderate to Severe Symptoms: Reserpine and tetrabenazine
	*New drug approved 2017		*New drug approved 2017

	**Austedo ([[deutetrabenazine]]), previously approved for chorea due to Huntington's disease		**Austedo ([[deutetrabenazine]]), previously approved for chorea due to Huntington's disease
	**12-48 mg/day PO divided BID, starting at 6 mg BID, increased by 6 mg/day qwk		**12-48 mg/day PO divided BID, starting at 6 mg BID, increased by 6 mg/day qwk

2018-10-10T22:35:15Z

Management

← Revisión anterior		Revisión del 22:35 10 oct 2018
Línea 16:		Línea 16:

	==Management==		==Management==
	*Mild Symptoms: Cessation of the neuroleptic drug or decreasing the dose		*Mild Symptoms: Cessation of the neuroleptic drug or decreasing the dose, which rarely reverses symptoms
	*Moderate to Severe Symptoms: Reserpine and tetrabenazine		*Moderate to Severe Symptoms: Reserpine and tetrabenazine
			*New drug approved 2017

			**Austedo ([[deutetrabenazine]]), previously approved for chorea due to Huntington's disease
			**12-48 mg/day PO divided BID, starting at 6 mg BID, increased by 6 mg/day qwk

	==See Also==		==See Also==

2018-10-10T22:31:33Z

Background

← Revisión anterior		Revisión del 22:31 10 oct 2018
Línea 4:		Línea 4:
	**Grimacing, Tongue movements, Lip smacking, Excessive eye blinking		**Grimacing, Tongue movements, Lip smacking, Excessive eye blinking
	*Often occurs after years of treatment with neuroleptic agents		*Often occurs after years of treatment with neuroleptic agents
			*Risk factors:
			**Longer duration of neuroleptic treatment
			**Concomitant mood disorder
			**Patient age, particularly elderly females

	==Evaluation==		==Evaluation==

2018-10-10T22:29:56Z

Differential Diagnosis

2018-10-10T22:28:39Z

Evaluation

2016-07-25T19:03:27Z

Text replacement - "==Diagnosis==" to "==Evaluation=="

← Revisión anterior		Revisión del 19:03 25 jul 2016
Línea 5:		Línea 5:
	*Often occurs after years of treatment with neuroleptic agents		*Often occurs after years of treatment with neuroleptic agents

	==~~Diagnosis~~==		==Evaluation==

	==Differential Diagnosis==		==Differential Diagnosis==

2016-06-28T01:20:50Z

Text replacement - "== Source ==" to "==References== <references/>"

← Revisión anterior		Revisión del 01:20 28 jun 2016
Línea 16:		Línea 16:
	*[[Seizure]]		*[[Seizure]]

	== ~~Source~~ ==		==References==
			<references/>
	*Hockberger RS, Richards JR: Thought Disorders; in Marx JA, Hockberger RS, Walls RM, et al (eds): Rosen’s Emergency Medicine: Concepts and Clinical Practice, ed 8. St. Louis, Mosby, Inc., 2014, (Ch) 110: p 1460-1466		*Hockberger RS, Richards JR: Thought Disorders; in Marx JA, Hockberger RS, Walls RM, et al (eds): Rosen’s Emergency Medicine: Concepts and Clinical Practice, ed 8. St. Louis, Mosby, Inc., 2014, (Ch) 110: p 1460-1466

	[[Category:Neurology]]		[[Category:Neurology]]

2016-03-22T14:14:24Z

Text replacement - "Category:Neuro" to "Category:Neurology"

← Revisión anterior		Revisión del 14:14 22 mar 2016
Línea 19:		Línea 19:
	*Hockberger RS, Richards JR: Thought Disorders; in Marx JA, Hockberger RS, Walls RM, et al (eds): Rosen’s Emergency Medicine: Concepts and Clinical Practice, ed 8. St. Louis, Mosby, Inc., 2014, (Ch) 110: p 1460-1466		*Hockberger RS, Richards JR: Thought Disorders; in Marx JA, Hockberger RS, Walls RM, et al (eds): Rosen’s Emergency Medicine: Concepts and Clinical Practice, ed 8. St. Louis, Mosby, Inc., 2014, (Ch) 110: p 1460-1466

	[[Category:~~Neuro~~]]		[[Category:Neurology]]

2015-12-30T02:01:57Z